{
    "root": "72b1786a-3437-4799-8214-f37b5be5607c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Onivyde",
    "value": "20250303",
    "ingredients": [
        {
            "name": "IRINOTECAN HYDROCHLORIDE",
            "code": "042LAQ1IIS",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_80630"
        },
        {
            "name": "1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE",
            "code": "043IPI2M0K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB02144"
        },
        {
            "name": "CHOLESTEROL",
            "code": "97C5T2UQ7J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16113"
        },
        {
            "name": "SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE",
            "code": "3L6NN8ZZKU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "HYDROXYETHYLPIPERAZINE ETHANE SULFONIC ACID",
            "code": "RWW266YE9I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_42266"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        }
    ],
    "indications": {
        "text": "onivyde indicated , combination oxaliplatin , fluorouracil leucovorin first-line treatment adult patients metastatic pancreatic adenocarcinoma . onivyde indicated , combination fluorouracil leucovorin , treatment adult patients metastatic pancreatic adenocarcinoma disease progression following gemcitabine-based therapy . limitations : onivyde indicated single agent treatment patients metastatic pancreatic adenocarcinoma . [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "pancreatic adenocarcinoma (DOID:4074)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4074"
            },
            {
                "text": "adenocarcinoma (DOID:299)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_299"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "substitute onivyde drugs containing irinotecan hcl . ( 2.1 ) onivyde combination oxaliplatin , fluorouracil leucovorin : recommended dose onivyde 50 mg/m 2 intravenous infusion 90 minutes every two weeks . ( 2.2 ) recommended starting dose onivyde patients homozygous ugt1a1 * 28 50 mg/m 2 every two weeks . ( 2.2 ) recommended dose onivyde patients serum bilirubin upper limit normal . ( 2.2 ) onivyde combination fluorouracil leucovorin : recommended dose onivyde 70 mg/m 2 intravenous infusion 90 minutes every two weeks . ( 2.2 ) recommended starting dose onivyde patients homozygous ugt1a1 * 28 50 mg/m 2 every two weeks . ( 2.2 ) recommended dose onivyde patients serum bilirubin upper limit normal . ( 2.2 ) premedicate corticosteroid anti-emetic 30 minutes prior onivyde . ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "onivyde contraindicated patients experienced severe hypersensitivity reaction anaphylaxis onivyde irinotecan hcl . [ ( 5.4 ) , ( 6.2 ) ] .",
    "indications_original": "ONIVYDE is indicated, in combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma.\n                     \n                     ONIVYDE is indicated, in combination with fluorouracil and leucovorin, for the treatment of adult patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy.\n                  \n                  Limitations of Use: ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic pancreatic adenocarcinoma. [see Clinical Studies (14)].",
    "contraindications_original": "Do not substitute ONIVYDE for other drugs containing irinotecan HCl. ( 2.1 ) ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin: Recommended dose of ONIVYDE is 50 mg/m 2 intravenous infusion over 90 minutes every two weeks. ( 2.2 ) Recommended starting dose of ONIVYDE in patients homozygous for UGT1A1*28 is 50 mg/m 2 every two weeks. ( 2.2 ) There is no recommended dose of ONIVYDE for patients with serum bilirubin above the upper limit of normal. ( 2.2 ) ONIVYDE in combination with fluorouracil and leucovorin: Recommended dose of ONIVYDE is 70 mg/m 2 intravenous infusion over 90 minutes every two weeks. ( 2.2 ) Recommended starting dose of ONIVYDE in patients homozygous for UGT1A1*28 is 50 mg/m 2 every two weeks. ( 2.2 ) There is no recommended dose of ONIVYDE for patients with serum bilirubin above the upper limit of normal. ( 2.2 ) Premedicate with a corticosteroid and an anti-emetic 30 minutes prior to ONIVYDE. ( 2.2 )",
    "adverseReactions_original": "ONIVYDE is contraindicated in patients who have experienced a severe hypersensitivity reaction or anaphylaxis to ONIVYDE or irinotecan HCl. [see Warnings and Precautions (5.4), Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Onivyde",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_80630"
        }
    ]
}